Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer

[1]  A. Patiño-García,et al.  FHL2 Silencing Reduces Wnt Signaling and Osteosarcoma Tumorigenesis In Vitro and In Vivo , 2013, PloS one.

[2]  M. Buendia,et al.  The Four and a Half LIM-only Protein 2 (FHL2) Activates Transforming Growth Factor β (TGF-β) Signaling by Regulating Ubiquitination of the E3 Ligase Arkadia* , 2012, The Journal of Biological Chemistry.

[3]  K. Mayo,et al.  The LIM domain protein FHL2 interacts with the NR5A family of nuclear receptors and CREB to activate the inhibin-α subunit gene in ovarian granulosa cells. , 2012, Molecular endocrinology.

[4]  L. Bargelloni,et al.  Overexpression of four and a half LIM domains protein 2 promotes epithelial-mesenchymal transition-like phenotype in fish pre-osteoblasts. , 2012, Biochimie.

[5]  Jinhyuk Lee,et al.  Computational Prediction of Protein-Protein Interactions of Human Tyrosinase , 2012, Enzyme research.

[6]  G. Semenza,et al.  Four-and-a-Half LIM Domain Proteins Inhibit Transactivation by Hypoxia-inducible Factor 1* , 2012, The Journal of Biological Chemistry.

[7]  D. Geerts,et al.  FHL2 Protein Is a Novel Co-repressor of Nuclear Receptor Nur77* , 2011, The Journal of Biological Chemistry.

[8]  W. Fiedler,et al.  Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. , 2011, Anti-cancer agents in medicinal chemistry.

[9]  Christoph Engel,et al.  FHL2 expression in peritumoural fibroblasts correlates with lymphatic metastasis in sporadic but not in HNPCC-associated colon cancer , 2011, Laboratory Investigation.

[10]  C. Sardet,et al.  Four-and-a-half LIM protein 2 promotes invasive potential and epithelial-mesenchymal transition in colon cancer. , 2010, Carcinogenesis.

[11]  C. Morrison,et al.  Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. , 2010, Gynecologic oncology.

[12]  Hideo Baba,et al.  Epithelial–mesenchymal transition in cancer development and its clinical significance , 2010, Cancer science.

[13]  F. Xu,et al.  Functional gene silencing mediated by chitosan/siRNA nanocomplexes , 2009, Nanotechnology.

[14]  Isabelle Salmon,et al.  Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis , 2009, Proteomics.

[15]  Xiaobing Fu,et al.  FHL2 interacts with and acts as a functional repressor of Id2 in human neuroblastoma cells , 2009, Nucleic acids research.

[16]  Jide Wang,et al.  The four‐and‐a‐half‐LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities , 2008, Glia.

[17]  G. Berx,et al.  Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front , 2008, Histochemistry and Cell Biology.

[18]  D. Radisky,et al.  Mechanisms of Disease: epithelial–mesenchymal transition—does cellular plasticity fuel neoplastic progression? , 2008, Nature Clinical Practice Oncology.

[19]  B. Jiang,et al.  Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. , 2007, Gastroenterology.

[20]  R. Schüle,et al.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. , 2006, Cancer research.

[21]  U. Moens,et al.  The multifunctional roles of the four-and-a-half-LIM only protein FHL2 , 2006, Cellular and Molecular Life Sciences CMLS.

[22]  R. Schüle,et al.  Expression of the Transcriptional Coregulator FHL2 in Human Breast Cancer: A Clinicopathologic Study , 2006, The Journal of the Society for Gynecologic Investigation: JSGI.

[23]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[24]  M. Beckerle,et al.  The LIM domain: from the cytoskeleton to the nucleus , 2004, Nature Reviews Molecular Cell Biology.

[25]  R. Schüle,et al.  The LIM-only Proteins FHL2 and FHL3 Interact with α- and β-Subunits of the Muscle α7β1 Integrin Receptor* , 2004, Journal of Biological Chemistry.

[26]  E. Bruyneel,et al.  Tenascin‐C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  R. Schüle,et al.  Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. , 2004, Anticancer research.

[28]  Jing-hua Yan,et al.  [Mapping of FHL2 transcription activation domain]. , 2003, Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica.

[29]  Susan S. Brown,et al.  FHL3 is an actin-binding protein that regulates alpha-actinin-mediated actin bundling: FHL3 localizes to actin stress fibers and enhances cell spreading and stress fiber disassembly. , 2003, The Journal of biological chemistry.

[30]  P. Sassone-Corsi,et al.  The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Buendia,et al.  Identification of the LIM Protein FHL2 as a Coactivator of β-Catenin* , 2003, The Journal of Biological Chemistry.

[32]  Daniel Auerbach,et al.  Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2 , 2002, Journal of Cell Science.

[33]  J. Licht,et al.  The LIM-only Protein DRAL/FHL2 Interacts with and Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein* , 2002, The Journal of Biological Chemistry.

[34]  S. Rétaux,et al.  A short history of LIM domains (1993–2002) , 2002, Molecular Neurobiology.

[35]  Hong Wang,et al.  Screening the proteins that interact with calpain in a human heart cDNA library using a yeast two-hybrid system. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[36]  J. G. Patton,et al.  An RNA recognition motif (RRM) is required for the localization of PTB-associated splicing factor (PSF) to subnuclear speckles. , 2001, Experimental cell research.

[37]  B. Schäfer,et al.  Dral Is a P53-Responsive Gene Whose Four and a Half Lim Domain Protein Product Induces Apoptosis , 2000, The Journal of cell biology.

[38]  S. Tsui,et al.  Protein‐protein interaction of FHL2, a LIM domain protein preferentially expressed in human heart, with hCDC47 , 2000, Journal of cellular biochemistry.

[39]  K P Fung,et al.  Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. , 1998, Gene.

[40]  B. Schäfer,et al.  Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. , 1997, DNA and cell biology.

[41]  G. Berx,et al.  Transition from the noninvasive to the invasive phenotype and loss of alpha-catenin in human colon cancer cells. , 1995, Cancer research.

[42]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[43]  C. Sardet,et al.  Four and a half LIM protein 2 (FHL2) negatively regulates the transcription of E-cadherin through interaction with Snail1. , 2011, European journal of cancer.

[44]  R. Schüle,et al.  The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha7beta1 integrin receptor. , 2004, The Journal of biological chemistry.

[45]  M. Waye,et al.  Interaction of the heart‐specific LIM domain protein, FHL2, with DNA‐binding nuclear protein, hNP220 , 2002, Journal of cellular biochemistry.

[46]  T. Heinemeyer,et al.  Databases on transcriptional regulation : TRANSFAC , TRRD and COMPEL , 1997 .

[47]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.